Checks blood samples for gene changes in patients with advanced solid tumors
Studies gene changes in blood samples from adults with advanced solid tumors receiving treatment.
Key facts
- Who runs it
- Centro di Riferimento Oncologico - Aviano
- Where
- Aviano, ItalySee the site
- Trial code
- Registry title
- A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
- Status
- Recruiting
- People taking part
- 782 people, planned
- Started
- 26 May 2023
- Expected to end
- 31 May 2030
- Type of study
- Observational
- Record updated
- 13 September 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or locally advanced solid tumors who are about to start standard therapy. A blood test (liquid biopsy) will look for gene changes.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced or locally advanced solid tumor proven by tissue examination. Examples: stage IV colon-rectal, gastric or breast cancer; advanced ovarian, endometrial or cervical cancer; pancreatic, bile duct and liver cancer; vulva cancer; melanoma.
- Earlier treatment
- People are about to start standard therapy at a set treatment line, for example first, second or third line for colon-rectal cancer, or first-line for bile duct cancer. Third-line melanoma therapy counts only for BRAF-mutated melanoma.
Main reasons for not taking part
- Another cancer in the last 3 years (except adequately treated basal or squamous cell skin cancer, or carcinoma in situ of the cervix)
- Cannot or will not do the study assessments at the four planned timepoints
- Cannot understand or sign the informed consent form
- Not willing or able to follow scheduled visits and tests
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Patients eligible for inclusion in this study have to meet all of the following criteria:
- Patients, 18 years of age or older
- Competent and able to comprehend, sign and date an Ethics Committee (EC) approved Informed Consent Form (ICF) before performance of any study-specific procedures or tests
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
- Histologically proven diagnosis solid tumor
- Diagnosis of advanced or locally advanced disease
- Patients candidated to receive standard therapy in the following line:
- first, second or third-line therapy for colon-rectal cancer in IV stage
- first or second-line therapy for gastric cancer in IV stage
- primary intent or first-line therapy for pancreatic cancer
- first-line therapy for bile duct cancer
- first or second-line therapy for hepatocarcinoma
- first, second, third, fourth or fifth-line therapy for breast cancer in IV stage
- chemotherapy for ovarian cancer in advanced stage (FIGO III-IV) and at the time of first relapse
- first or second-line therapy for endometrial cancer in advanced stage (FIGO III-IV)
- first or second-line therapy for advanced or locally advanced cervical cancer
- therapy for locally advanced or first line therapy for metastatic vulva cancer
- first, second or third-line therapy for melanoma (third-line therapy only in BRAF-mutated melanoma)
Who cannot take part
- Diagnosis of any secondary malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix
- Patients unable or unwilling to undergo as per protocol assessments at the four planned timepoints
Where in Italy
- IRCCS, Centro di Riferimento Oncologico (CRO) di AvianoAviano, ItalyContact: Fabio Puglisi, MD, PhDTaking people
About the trial
What the trial wants to find out
The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA. Among these, the Next generation sequencing (NGS) is a technique that consists in sequencing several genomes in a short time span, collecting information about a wider range of genomic alterations, using small quantities of genetic material. It is used to identify potential circulating dynamic biomarkers of treatment sensitivity or resistance in a real word multi-pathology evaluation. In this way, defining the mutational status of clinical relevance genes in real world, as a predictive biomarker to identify those patients most likely to benefit from target therapy, offers the potential to optimize access to further therapies. The aim of this study is to evaluate the real-world prevalence of clinically useful mutations in patients who are receiving therapy for advanced and locally advanced solid tumor through liquid biopsy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Prospective, Observational Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
- Plain-language title
- Checks blood samples for gene changes in patients with advanced solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 September 2023